SLC2A1 and breast carcinoma: Widely recognized as a prognostic factor in many cancers, glucose transporter-1 (GLUT1) is associated with both a poor prognosis and drug resistance in cancers, such as PanC, cervical cancer, and breast cancer (Nagarajan et al., 2017; He et al., 2019; Kim and Chang, 2019).